Angiex is conducting a Phase I clinical trial of AGX101, an investigational TM4SF1-directed ND-ADC. AGX101 is designed to bind TM4SF1 and deliver a cytotoxic payload to TM4SF1-expressing tumor cells and tumor-associated endothelial cells. This dual-targeting approach is intended to address both tumor cells and tumor vasculature.

The trial is currently enrolling patients with unresectable, locally advanced or metastatic solid tumors. The collaboration will include longitudinal Signatera testing for circulating tumor DNA (ctDNA) to explore its value for treatment response monitoring during AGX101 treatment.

Natera’s Signatera test provides a personalized measure of ctDNA that may complement radiologic assessment. Longitudinal ctDNA assessments may provide additional information in patients treated with AGX101, particularly when imaging shows metabolic or structural changes whose relationship to viable tumor is uncertain.

"We believe AGX101 has the potential to offer a differentiated therapeutic approach for patients with advanced solid tumors," said Paul Jaminet, Ph.D., co-founder and CEO of Angiex. "This collaboration will allow us to evaluate whether longitudinal ctDNA measurements can complement imaging and improve our understanding of treatment response."

"Signatera provides additional depth into early biologic response assessment that can meaningfully advance our understanding of this novel drug class," said Eric Matthews, general manager, biopharma, at Natera. "We look forward to working with the Angiex team to generate molecular response data that can inform the development of AGX101 and advance this promising therapeutic approach."